nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical Universitynefr-127Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИ КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯORIGINAL ARTICLES CLINICAL STUDIESФактор роста фибробластов-23 и сердечнососудистые осложнения при хронической болезни почекThe fibroblast growth factor-23 and cardiovascular complications in chronic kidney diseaseДзгоеваФ. У.DzgoevaF. U.fdzgoeva@mail.ruСопоевМ. Ю.SopoevM. Y.noemail@neicon.ruБестаеваТ. Л.BestaevaT. L.noemail@neicon.ruХамицаеваО. В.KhamitsaevaO. V.noemail@neicon.ruГиголаевД. А.GigolaevD. A.noemail@neicon.ruСеверо-Осетинская государственная медицинская академияРоссияNorth Osetian Medical State AcademiaRussian FederationРеспубликанская клиническая больницаРоссияRepublican clinical hospitalRussian FederationСеверо-Кавказский многопрофильный медицинский центр, гРоссияNorth Caucasian multidisciplinary medical centerRussian Federation2015010920151954956Copyright © Дзгоева Ф.У., Сопоев М.Ю., Бестаева Т.Л., Хамицаева О.В., Гиголаев Д.А., 20152015Дзгоева Ф.У., Сопоев М.Ю., Бестаева Т.Л., Хамицаева О.В., Гиголаев Д.А.Dzgoeva F.U., Sopoev M.Y., Bestaeva T.L., Khamitsaeva O.V., Gigolaev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/127

ЦЕЛЬ: установить возможную взаимосвязь между уровнем фактора роста фибробластов-23 (FFG-23) в сыворотке крови и показателями морфофункционального состояния левого желудочка, сосудистой стенки аорты и крупных артерий у больных на разных стадиях хронической болезни почек (ХБП). ПАЦИЕНТЫ И МЕТОДЫ. В обследование включили 105 больных с ХБП С1-5 стадии (50 мужчин и 55женщин в возрасте от 34 до 62 лет, средний возраст составил 48±4,5 года). Стадии ХБП определяли согласно критериям NKF-K/DOQI, скорость клубочковой фильтрации рассчитывали по формуле CKD-EPI. FGF-23 определяли у всех больных с использованием коммерческих иммуноферментных наборов. Для оценки морфофункционального состояния левого желудочка, аорты, артерий проводили эхокардиографическое исследование с допплерографией. РЕЗУЛЬТАТЫ. У обследованных больных по мере прогрессирования ХБП от С1до С5 стадии выявлено нарастание концентрации в сыворотке крови FGF-23. Между уровнем FGF-23 и морфофункциональными показателями поражения ЛЖ отмечена сильная прямая корреляция, сохранявшая свое значение при анализе исследуемых факторов как в зависимости от функционального состояния почек, так и от характера поражения сердечно-сосудистой системы.ЗАКЛЮЧЕНИЕ. Морфогенетический белок FGF-23 играет значимую роль не только в процессах ремоделирования костной ткани, но и в развитии кардиоваскулярных осложнений при ХБП.

THE AIM: to establish possible interaction between fibroblast growth factor 23 (FGF-23) increase in blood serum and factors of left ventricular morphofunctional state, aortic and big arteries wall in patients with chronic kidney disease (CKD) different stages. PATIENTS AND METHODS. 105 Patients (50 men and 55women) aged 34 to 62 years ( mean age 48±4,5 years) with Stages 1-5 CKD were examined. CKD stages were determined in accordance with the NKF-K/DOQI guidelines; glomerular filtration rate was calculated using the CKD-EPI formula. Serum FGF-23 was examined in all patients, by applying commercial enzyme immunoassay kits. Doppler echocardiography was performed to evaluate left ventricle (LV), aorta, arteries morphofunctional state. RESULTS. As renal failure progressed from Stage 1 to Stage 5 CKD, the examined patients had higher serum FGF-23 concentration. The level of FGF-23 and the morphofunctional indicators of LV lesion showed a strong direct correlation that preserved its significance in analyzing the factors in question in relation to the function of the kidneys and the pattern of cardiovascular system lesion. CONCLUSION. The morphogenetic protein FGF-23 seem to play a significant role not only in bone remodeling processes, but also in the development of CVEs in CKD.

фактор роста фибробластов-23хроническая болезнь почексердечно-сосудистые осложнениянарушения костно-минерального обменаfibroblast growth factor 23chronic kidney diseasecardiovascular eventsbone mineral metabolic disturbancesReferencesМухин НА. Хроническая болезнь почек. Клин фармакол и тер 2011;4:70-75 [Muhin NA. Chronic kidney disease. Klin farmakol i ter 2011;4:70-75]Мухин НА. Хроническая болезнь почек. Клин фармакол и тер 2011;4:70-75 [Muhin NA. Chronic kidney disease. Klin farmakol i ter 2011;4:70-75]Смирнов АВ, Румянцев АШ, Добронравов ВА, Каюков ИГ. XXI век - время интегративной нефрологии. Нефрология 2015;2:26-32 [Smirnov AV, Rumyantsev Ash, Dobronravov VA, Kayukov IG. The twenty-first century integrative Nephrology. Nefrologiya 2015;2:26-32]Смирнов АВ, Румянцев АШ, Добронравов ВА, Каюков ИГ. XXI век - время интегративной нефрологии. Нефрология 2015;2:26-32 [Smirnov AV, Rumyantsev Ash, Dobronravov VA, Kayukov IG. The twenty-first century integrative Nephrology. Nefrologiya 2015;2:26-32]Dhingra R, Gaziano JM, Djoussé L. Chronic kidney disease and the risk of heart failure in men. Circ Heart Fail 2011;4: 138-144Dhingra R, Gaziano JM, Djoussé L. Chronic kidney disease and the risk of heart failure in men. Circ Heart Fail 2011;4: 138-144Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12: 1079-1084Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12: 1079-1084Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747Ix JH, Katz R, Kestenbaum BR. et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60:200-207Ix JH, Katz R, Kestenbaum BR. et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60:200-207Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121: 4393-4408Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121: 4393-4408Scialla J, Lau W, Reilly M et al. Chronic Renal Insufficiency Cohort Study Investigators. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83: 1159-1168Scialla J, Lau W, Reilly M et al. Chronic Renal Insufficiency Cohort Study Investigators. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83: 1159-1168Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: Роль фактора роста фибробластов-23 и Klotho. Нефрология 2011;4:11-20 [Dobronravov VA. Modern view on the pathophysiology of secondary hyperparathyroidism: the Role of fibroblast growth factor-23 and Klotho. Nefrologiya 2011;4:11-20]Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: Роль фактора роста фибробластов-23 и Klotho. Нефрология 2011;4:11-20 [Dobronravov VA. Modern view on the pathophysiology of secondary hyperparathyroidism: the Role of fibroblast growth factor-23 and Klotho. Nefrologiya 2011;4:11-20]Ketteler M, Biggar R. FGF23: more a matter of the heart than of the vessels? Nephrol Dial Transplant 2014; 29: 1987-1988Ketteler M, Biggar R. FGF23: more a matter of the heart than of the vessels? Nephrol Dial Transplant 2014; 29: 1987-1988Милованова ЛЮ, Милованов ЮС, Козловская ЛВ, Мухин НА. Новые маркеры кардиоренальных взаимосвязей при хронической болезни почек. Тер арх 2013; 6:17-24 [Milovanova LYu, Milovanov YuS, Kozlovskaya LV, Muhin NA. New markers of cardiorenal interactions in chronic kidney disease. Ter arh 2013; 6:17-24]Милованова ЛЮ, Милованов ЮС, Козловская ЛВ, Мухин НА. Новые маркеры кардиоренальных взаимосвязей при хронической болезни почек. Тер арх 2013; 6:17-24 [Milovanova LYu, Milovanov YuS, Kozlovskaya LV, Muhin NA. New markers of cardiorenal interactions in chronic kidney disease. Ter arh 2013; 6:17-24]Lutsey PL, Alonso A, Selvin E et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J Am Heart Assoc 2014;3:e000936Lutsey PL, Alonso A, Selvin E et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J Am Heart Assoc 2014;3:e000936Isakova T, Craven TE, Lee J et al. Fibroblast Growth Factor 23 and Incident CKD in Type 2 Diabetes. JASN 2015 ; 10 : 29-38Isakova T, Craven TE, Lee J et al. Fibroblast Growth Factor 23 and Incident CKD in Type 2 Diabetes. JASN 2015 ; 10 : 29-38Wang L, Song X Manson JE et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012;5:819-829.Wang L, Song X Manson JE et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012;5:819-829.Рафрафи Х., Румянцев А.Ш. Статус витамина D и состояние сердечно-сосудистой системы у пациентов с хронической болезнью почек С5д стадии. Нефрология 2015; 19(4)51-54 [Rafrafi H., Rumjancev A.Sh. Status vitamina D i sostojanie serdechno-sosudistoj sistemy u pacientov s hronicheskoj bolezn’ju pochek S5d stadii. Nefrologija 2015; 19(4)51-54].Рафрафи Х., Румянцев А.Ш. Статус витамина D и состояние сердечно-сосудистой системы у пациентов с хронической болезнью почек С5д стадии. Нефрология 2015; 19(4)51-54 [Rafrafi H., Rumjancev A.Sh. Status vitamina D i sostojanie serdechno-sosudistoj sistemy u pacientov s hronicheskoj bolezn’ju pochek S5d stadii. Nefrologija 2015; 19(4)51-54].Cozzolino M, Cosa F, Ciceri F et al. Vascular calcification in chronic kidney disease. EMJ Neph. 2013;1:46-51.Cozzolino M, Cosa F, Ciceri F et al. Vascular calcification in chronic kidney disease. EMJ Neph. 2013;1:46-51.Desai CS, Ning H, Lloyd-Jones DM et al. Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the Atherosclerosis Risk in Communities Study. Heart 2012; 98:330-334Desai CS, Ning H, Lloyd-Jones DM et al. Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the Atherosclerosis Risk in Communities Study. Heart 2012; 98:330-334Isakova T, Xie H, Yang W et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439Isakova T, Xie H, Yang W et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439Батюшин ММ, Левицкая ЕС, Терентьев ВП и др. Оценка влияния «почечных» факторов риска и параметров коронарной бляшки на сердечно-сосудистый прогноз у больных с ишемической болезнью сердца. Кардиоваскулярная терапия и профилактика 2011;4:59-62 3 [Batyushin MM, Levitskaya ES, Terentev VP et al. Evaluation of the effect of renal risk factors and parameters of coronary plaques on cardiovascular prognosis in patients with coronary heart disease. Kardiovaskulyarnaya terapiya i profilaktika2011;4:59-62 3]Батюшин ММ, Левицкая ЕС, Терентьев ВП и др. Оценка влияния «почечных» факторов риска и параметров коронарной бляшки на сердечно-сосудистый прогноз у больных с ишемической болезнью сердца. Кардиоваскулярная терапия и профилактика 2011;4:59-62 3 [Batyushin MM, Levitskaya ES, Terentev VP et al. Evaluation of the effect of renal risk factors and parameters of coronary plaques on cardiovascular prognosis in patients with coronary heart disease. Kardiovaskulyarnaya terapiya i profilaktika2011;4:59-62 3]Sloan A, Isakova T, Gutiérrez OM et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408Sloan A, Isakova T, Gutiérrez OM et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408Gutiérrez OM, Wolf M, Taylor EN et al. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011; 6: 2871-2878Gutiérrez OM, Wolf M, Taylor EN et al. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011; 6: 2871-2878Scialla JJ, Xie H, Rahman M et al. Fibroblast Growth Factor-23 and Cardiovascular Events in CKD JASN February 2014 ;25: 349-360Scialla JJ, Xie H, Rahman M et al. Fibroblast Growth Factor-23 and Cardiovascular Events in CKD JASN February 2014 ;25: 349-360Ärnlöv J, Carlsson AC, Sundström J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013: 83:160-166Ärnlöv J, Carlsson AC, Sundström J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013: 83:160-166Seiler S, Cremers B, Rebling NM et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 2688-2696Seiler S, Cremers B, Rebling NM et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 2688-2696Bengtson LGS, Lutsey PL, Loehr LR et al. Fibroblast Growth Factor-23 and Incident Coronary Heart Disease, Heart Failure, and Cardiovascular Mortality: The Atherosclerosis Risk In Communities Study. J Am Heart Assoc 2014; 3: e000936Bengtson LGS, Lutsey PL, Loehr LR et al. Fibroblast Growth Factor-23 and Incident Coronary Heart Disease, Heart Failure, and Cardiovascular Mortality: The Atherosclerosis Risk In Communities Study. J Am Heart Assoc 2014; 3: e000936Mathew JS, Sachs MC, Katz R et al. Fibroblast growth factor-23 and incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 2014;130:298-307Mathew JS, Sachs MC, Katz R et al. Fibroblast growth factor-23 and incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 2014;130:298-307Hsu JJ, Katz R, Ix J et al. Association of fibroblast growth factor-23 with arterial stiffness in the Multiethnic Study of Atherosclerosis (MESA). Nephrol Dial Transplant 2014;29:2099-2105Hsu JJ, Katz R, Ix J et al. Association of fibroblast growth factor-23 with arterial stiffness in the Multiethnic Study of Atherosclerosis (MESA). Nephrol Dial Transplant 2014;29:2099-2105Дзгоева ФУ, Гатагонова ТМ, Бестаева ТЛ и др. Остеопротегерин и фактор роста фибробластов (FGF-23) в развитии кардиоваскулярных осложнений при хронической болезни почек. Тер арх 2014;6:63-69 [Dzgoeva FU, Gatagonova TM, Bestaeva TL et al. The osteoprotegerin and fibroblast growth factor (FGF-23) in the development of cardiovascular complications in chronic kidney disease. Ter arh 2014;6:63-69]Дзгоева ФУ, Гатагонова ТМ, Бестаева ТЛ и др. Остеопротегерин и фактор роста фибробластов (FGF-23) в развитии кардиоваскулярных осложнений при хронической болезни почек. Тер арх 2014;6:63-69 [Dzgoeva FU, Gatagonova TM, Bestaeva TL et al. The osteoprotegerin and fibroblast growth factor (FGF-23) in the development of cardiovascular complications in chronic kidney disease. Ter arh 2014;6:63-69]Дзгоева ФУ, Гатагонова ТМ, Кочисова ЗХ и др. Взаимосвязь типов ремоделирования левого желудочка с показателями оксидативного стресса, фосфорно-кальциевого и липидного обмена при терминальной почечной недостаточности. Нефрология 2013 ;5: 35 38 [Dzgoeva FU, Gatagonova TM, Kochisova ZH et al. The correlation between types of left ventricular remodeling with indicators of oxidative stress, calcium and phosphorus and lipid metabolism in end-stage renal failure. Nefrologiya 2013 ;5: 35-38]Дзгоева ФУ, Гатагонова ТМ, Кочисова ЗХ и др. Взаимосвязь типов ремоделирования левого желудочка с показателями оксидативного стресса, фосфорно-кальциевого и липидного обмена при терминальной почечной недостаточности. Нефрология 2013 ;5: 35 38 [Dzgoeva FU, Gatagonova TM, Kochisova ZH et al. The correlation between types of left ventricular remodeling with indicators of oxidative stress, calcium and phosphorus and lipid metabolism in end-stage renal failure. Nefrologiya 2013 ;5: 35-38]Munoz MJ, Isakova T, Ricardo AC et al. Cohort ftCRI. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 2012; 7:1155-1162Munoz MJ, Isakova T, Ricardo AC et al. Cohort ftCRI. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 2012; 7:1155-1162Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: 640-648.Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: 640-648.Arnlov J, Carlsson AC, Sundstrom J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013; 83:160-166.Arnlov J, Carlsson AC, Sundstrom J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013; 83:160-166.Rosamond WD, Chang PP, Baggett C et al. Classification of heart failure in the Atherosclerosis Risk in Communities (ARIC) Study: a comparison of diagnostic criteria. Circ Heart Fail 2012; 5:152-159.Rosamond WD, Chang PP, Baggett C et al. Classification of heart failure in the Atherosclerosis Risk in Communities (ARIC) Study: a comparison of diagnostic criteria. Circ Heart Fail 2012; 5:152-159.Добронравов ВА, Богданова EO. Патогенез нарушений обмена фосфатов при хронической болезни почек: все ли так ясно, как кажется? Нефрология 2014;2: 42-47 [Dobronravov VA, Bogdanova EO. The pathogenesis of disorders of metabolism of phosphate in chronic kidney disease: everything is so clear as it seems? Nefrologiya 2014;2: 42-47]Добронравов ВА, Богданова EO. Патогенез нарушений обмена фосфатов при хронической болезни почек: все ли так ясно, как кажется? Нефрология 2014;2: 42-47 [Dobronravov VA, Bogdanova EO. The pathogenesis of disorders of metabolism of phosphate in chronic kidney disease: everything is so clear as it seems? Nefrologiya 2014;2: 42-47]Nakano C, Hamano T, Fujii N et al. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 2012 ; 50:1266-1274Nakano C, Hamano T, Fujii N et al. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 2012 ; 50:1266-1274Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011;22: 124-136Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011;22: 124-136Foley RN, Collins AJ, Herzog CA et al. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study. Kidney Blood Press Res 2009; 32:37-44Foley RN, Collins AJ, Herzog CA et al. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study. Kidney Blood Press Res 2009; 32:37-44Lopez FL, Agarwal SK, Grams ME et al. Relation of serum phosphorus levels to the incidence of atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study).Am J Cardiol 2013; 111:857-862Lopez FL, Agarwal SK, Grams ME et al. Relation of serum phosphorus levels to the incidence of atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study).Am J Cardiol 2013; 111:857-862Di Marco GS, Reuter S, Kentrup D et al. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol. Dial. Transplant 2014;29 : 2028-2035Di Marco GS, Reuter S, Kentrup D et al. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol. Dial. Transplant 2014;29 : 2028-2035Nagano N, Miyata S, Abe M et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF-23 in renal failure rats. Kidney Int 2006; 69:531-537Nagano N, Miyata S, Abe M et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF-23 in renal failure rats. Kidney Int 2006; 69:531-537

The authors declare that there are no conflicts of interest present.